glp-1 molecular structure A) The of human GLP-1. B) The molecular structure PDB-101: Diabetes Mellitus: Diabetes Mellitus:

The amount of weight individuals can lose on tirzepatide is comparable to that achieved through surgical weight loss interventions without downtime or risk of complications

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications approved for the treatment of metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity (Wong et al., 2025)

A pilot study subsequently conducted by Holst in collaboration with Mette Zander at Hvidovre Hospital between September 1999 and October 2000 indicated that continuous subcutaneous infusions of synthetic GLP-1 over 6 weeks into patients with quite severe type 2 diabetes dramatically improved their blood sugar control, lowered glycated haemoglobin levels and decreased their body weight

These therapies mimic the action of the endogenous GLP-1 hormone to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite, making them highly effective for the management of type 2 diabetes and chronic weight management